Anti-Human PRAME Reference Antibody (GSK 2302032A)
- Catalog number: BS11836
- Availability: In Stock
$370.00
- Ex Tax: $370.00
Description: Anti-Human PRAME (GSK 2302032A) (BS11836) is a research-grade recombinant antibody targeting Opa-interacting protein 4. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Opa-interactingprotein4,Preferentiallyexpressedantigenofmelanoma,MAPE,OIP-4,Melanomaantigenpreferentiallyexpressedintumors,PRAME,OIP4
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: GSK-2302032A,GSK2302032A,GSK2302032A
Background: Melanoma antigen preferentially expressed in tumors (PRAME) is a ~57 kDa protein. Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation. The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding. In the nucleus, the CRL2(PRAME) complex is recruited to epigenetically and transcriptionally active promoter regions bound by nuclear transcription factor Y (NFY) and probably plays a role in chromstin regulation. Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG: prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis.
References:
1. Costessi, A. et al. (2011) The EMBO journal 30, 3786-98. PMID: 21822215
2. Lin, HC. et al. (2015) Science (New York, N.Y.) 349, 91-5. PMID: 2613898
3. Epping, MT. et al. (2005) Cell 122, 835-47. PMID: 16179254
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Opa-interactingprotein4,Preferentiallyexpressedantigenofmelanoma,MAPE,OIP-4,Melanomaantigenpreferentiallyexpressedintumors,PRAME,OIP4
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: GSK-2302032A,GSK2302032A,GSK2302032A
Background: Melanoma antigen preferentially expressed in tumors (PRAME) is a ~57 kDa protein. Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation. The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding. In the nucleus, the CRL2(PRAME) complex is recruited to epigenetically and transcriptionally active promoter regions bound by nuclear transcription factor Y (NFY) and probably plays a role in chromstin regulation. Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG: prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis.
References:
1. Costessi, A. et al. (2011) The EMBO journal 30, 3786-98. PMID: 21822215
2. Lin, HC. et al. (2015) Science (New York, N.Y.) 349, 91-5. PMID: 2613898
3. Epping, MT. et al. (2005) Cell 122, 835-47. PMID: 16179254
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
SDS-PAGESDS-PAGE for Research Grade Anti-Human PRAME (GSK 2302032A)
